Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia

Jorge J. Castillo, Andrew R. Branagan, David Sermer, Catherine A. Flynn, Kirsten Meid, Megan Little, Katherine Stockman, Timothy White, Alexa Canning, Maria L. Guerrera, Amanda Kofides, Shirong Liu, Xia Liu, Kris Richardson, Nicholas Tsakmaklis, Christopher J. Patterson, Zachary R. Hunter, Steven P. Treon, Shayna Sarosiek

Blood (2024) 143 (7): 582–591.

https://doi.org/10.1182/blood.2023022420

Published: 2024

Includes: Supplemental data

Journal Articles

Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia

Jorge J. Castillo, Shayna Sarosiek, Andrew R. Branagan, David J. Sermer, Catherine A. Flynn, Carly Leventoff, Megan Little, Timothy P White, Kirsten Meid, Alexa Canning, Maria Luisa Guerrera, Amanda Kofides, Xia Liu, Manit Munshi, Nicholas Tsakmaklis, Christopher J Patterson, Zachary R Hunter, Steven P Treon

Blood (2022) 140 (Supplement 1): 564–565.

https://doi.org/10.1182/blood-2022-155610

Published: 2022

Journal Articles

The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTK Cys481 ibrutinib resistance

Blood (2021) 138 (20): 1966–1979.

https://doi.org/10.1182/blood.2021011405

Published: 2021

Includes: Supplemental data

Journal Articles

Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia

Blood (2021) 138 (17): 1535–1539.

https://doi.org/10.1182/blood.2021012953

Published: 2021

Includes: Supplemental data

Journal Articles

Clinical and Genomic Factors Are Predictive of Response and Prognostic of Progression-Free Survival in Patients with Waldenström Macroglobulinemia Treated with Ibrutinib

Jorge J. Castillo, MD, Joshua Gustine, MPH, Maria Demos, Andrew Keezer, BS, Kirsten Meid, MPH, Gloria G Chan, MS, Jiaji G Chen, Maria Luisa Guerrera, MD, Amanda Kofides, Manit Munshi, MS, Nicholas Tsakmaklis, Xia Liu, MD, Lian Xu, MS, Guang Yang, PhD, Zachary R Hunter, PhD, Steven P Treon, MD PhD FRCP

Blood (2019) 134 (Supplement_1): 2823.

https://doi.org/10.1182/blood-2019-125069

Published: 2019

Journal Articles

CXCR4 Mutational Status Does Not Impact Outcomes in Patients with Waldenstrom Macroglobulinemia Treated with Proteasome Inhibitors

Jorge J. Castillo, MD, Joshua Gustine, MPH, Maria Demos, Andrew Keezer, BS, Kirsten Meid, MPH, Toni Dubeau, NP, Gloria G Chan, MS, Jiaji Chen, BS, Maria Luisa Guerrera, MD, Amanda Kofides, Manit Munshi, MS, Nicholas Tsakmaklis, Xia Liu, MD, Lian Xu, MS, Guang Yang, PhD, Zachary R Hunter, PhD, Steven P Treon, MD PhD FRCP

Blood (2019) 134 (Supplement_1): 2830.

https://doi.org/10.1182/blood-2019-122349

Published: 2019

Journal Articles

A Novel HCK and BTK Dual Inhibitor Kin-8194 Shows Superior Activity over Ibrutinib and Overcomes BTK C481S Mediated Ibrutinib Resistance in Vitro and In Vivo in MYD88 Mutated B-Cell Lymphomas

Guang Yang, PhD, Jinhua Wang, PhD, Xia Liu, MD, Manit Munshi, MS, Jiaji G Chen, Amanda Kofides, Lian Xu, MS, Nicholas Tsakmaklis, Maria Demos, Maria Luisa Guerrera, MD, Gloria G Chan, MS, Cristina Jimenez, PhD, Zachary R Hunter, PhD, Christopher Patterson, Jorge J. Castillo, MD, Sara J Buhrlage, PhD, Nathanael Gray, Steven P Treon, MD PhD FRCP

Blood (2019) 134 (Supplement_1): 394.

https://doi.org/10.1182/blood-2019-130636

Published: 2019

Journal Articles

Mutated MYD88 Regulates HCK Pro-Survival Signaling through JunB in MYD88 Mutated B-Lymphoma Cells

Xia Liu, MD, Jiaji G Chen, Manit Munshi, MS, Lian Xu, MS, Amanda Kofides, Nicholas Tsakmaklis, Maria Demos, Maria Luisa Guerrera, MD, Gloria G Chan, MS, Cristina Jimenez, PhD, Zachary R Hunter, PhD, Christopher Patterson, Kirsten Meid, MPH, Andrew Keezer, BS, Jorge J. Castillo, MD, Steven P Treon, MD PhD FRCP, Guang Yang, PhD

Blood (2019) 134 (Supplement_1): 3778.

https://doi.org/10.1182/blood-2019-130885

Published: 2019

Journal Articles

BTK Cys481Ser drives ibrutinib resistance via ERK1/2 and protects BTK wild-type MYD88-mutated cells by a paracrine mechanism

Blood (2018) 131 (18): 2047–2059.

https://doi.org/10.1182/blood-2017-10-811752

Published: 2018

Includes: Supplemental data

Journal Articles

Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia

Lian Xu, Nicholas Tsakmaklis, Guang Yang, Jiaji G. Chen, Xia Liu, Maria Demos, Amanda Kofides, Christopher J. Patterson, Kirsten Meid, Joshua Gustine, Toni Dubeau, M. Lia Palomba, Ranjana Advani, Jorge J. Castillo, Richard R. Furman, Zachary R. Hunter, Steven P. Treon

Blood (2017) 129 (18): 2519–2525.

https://doi.org/10.1182/blood-2017-01-761726

Published: 2017

Includes: Supplemental data

Journal Articles

Molecular Basis of Ibrutinib Resistance in Waldenstrom's Macroglobulinemia

Lian Xu, Nicholas Tsakmaklis, Guang Yang, PhD, Jiaji G Chen, Xia Liu, MD, Jie Chen, PhD, Maria Demos, Christopher J Patterson, MFA, Toni Dubeau, NP, Kirsten Meid, MPH, Joshua Gustine, MPH, Jorge J. Castillo, MD, Ranjana H Advani, MD, Maria Lia Palomba, MD, Richard R. Furman, MD, Zachary Hunter, PhD, Steven P Treon, MD PhD

Blood (2016) 128 (22): 756.

https://doi.org/10.1182/blood.V128.22.756.756

Published: 2016

Journal Articles

Acquisition of BTK C481S Produces Resistance to Ibrutinib in MYD88 Mutated WM and ABC DLBCL Cells That Is Accompanied By ERK1/2 Hyperactivation, and Is Targeted By the Addition of the ERK1/2 Inhibitor Ulixertinib

Jiaji G Chen, Xia Liu, MD, Jie Chen, PhD, Lian Xu, Nicholas Tsakmaklis, Maria Demos, Christopher J Patterson, MFA, Jorge J. Castillo, MD, Zachary Hunter, PhD, Steven P Treon, MD PhD, Guang Yang, PhD

Blood (2016) 128 (22): 2764.

https://doi.org/10.1182/blood.V128.22.2764.2764

Published: 2016

Journal Articles

HCK Transcription Is Regulated By AP1, NF-Kb and STAT3 Transcription Factors in MYD88 Mutated WM and ABC-DLBCL Cells

Xia Liu, MD, Jiaji G Chen, Jie Chen, PhD, Lian Xu, Nicholas Tsakmaklis, Maria Demos, Christopher J Patterson, MFA, Jorge J. Castillo, MD, Zachary Hunter, PhD, Steven P Treon, MD PhD, Guang Yang, PhD

Blood (2016) 128 (22): 2931.

https://doi.org/10.1182/blood.V128.22.2931.2931

Published: 2016

Journal Articles

Mutated MYD88 Zygosity and CXCR4 Mutation Status Are Important Determinants of Ibrutinib Response and Progression Free Survival in Waldenstrom's Macroglobulinemia

Steven P Treon, MD PhD, Nicholas Tsakmaklis, Kirsten Meid, MPH, Guang Yang, PhD, Jiaji G Chen, Xia Liu, MD, Jie Chen, PhD, Maria Demos, Christopher J Patterson, MFA, Toni Dubeau, NP, Joshua Gustine, MPH, Jorge J. Castillo, MD, Ranjana H Advani, MD, Maria Lia Palomba, MD, Lian Xu, Zachary Hunter, PhD

Blood (2016) 128 (22): 2984.

https://doi.org/10.1182/blood.V128.22.2984.2984

Published: 2016

Journal Articles

Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia

Zachary R. Hunter, Lian Xu, Guang Yang, Nicholas Tsakmaklis, Josephine M. Vos, Xia Liu, Jie Chen, Robert J. Manning, Jiaji G. Chen, Philip Brodsky, Christopher J. Patterson, Joshua Gustine, Toni Dubeau, Jorge J. Castillo, Kenneth C. Anderson, Nikhil M. Munshi, Steven P. Treon

Blood (2016) 128 (6): 827–838.

https://doi.org/10.1182/blood-2016-03-708263

Published: 2016

Includes: Supplemental data

Journal Articles

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib

Guang Yang, Sara J. Buhrlage, Li Tan, Xia Liu, Jie Chen, Lian Xu, Nicholas Tsakmaklis, Jiaji G. Chen, Christopher J. Patterson, Jennifer R. Brown, Jorge J. Castillo, Wei Zhang, Xiaofeng Zhang, Shuai Liu, Philip Cohen, Zachary R. Hunter, Nathanael Gray, Steven P. Treon

Blood (2016) 127 (25): 3237–3252.

https://doi.org/10.1182/blood-2016-01-695098

Published: 2016

Journal Articles

HCK Is a Highly Relevant Target of Ibrutinib in MYD88 Mutated Waldenstrom's Macroglobulinemia and Diffuse Large B-Cell Lymphoma

Guang Yang, PhD, Sara Buhrlage, PhD, Li Tan, PhD, Xia Liu, MD, Jie Chen, PhD, Zachary Hunter, PhD, Lian Xu, Nicholas Tsakmaklis, Jiaji Chen, Christopher J Patterson, MFA, Jorge J Castillo, MD, Wei Zhang, PhD, Nathanael Gray, PhD, Steven P Treon, MD PhD

Blood (2015) 126 (23): 705.

https://doi.org/10.1182/blood.V126.23.705.705

Published: 2015

Journal Articles

Targeting IRAK1/IRAK4 Signaling in Waldenstrom's Macroglobulinemia

Guang Yang, PhD, Xia Liu, MD, Jie Chen, PhD, Lian Xu, Nicholas Tsakmaklis, Jiaji Chen, Christopher J Patterson, MFA, Jorge J Castillo, MD, Philip Cohen, Li Tan, PhD, Sara Buhrlage, PhD, Nathanael Gray, PhD, Steven P Treon, MD PhD

Blood (2015) 126 (23): 4004.

https://doi.org/10.1182/blood.V126.23.4004.4004

Published: 2015

Journal Articles

The Clonal Architecture of CXCR4mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability

Blood (2015) 126 (23): 1486.

https://doi.org/10.1182/blood.V126.23.1486.1486

Published: 2015

Journal Articles

Targeting Myddosome Self-Assembly in Waldenstrom's Macroglobulinemia

Xia Liu, MD, Zachary Hunter, PhD, Lian Xu, Jie Chen, PhD, Jiaji Chen, Nicholas Tsakmaklis, Christopher J Patterson, MFA, Jorge J Castillo, MD, Sara Buhrlage, PhD, Nathanael Gray, PhD, Steven P Treon, MD PhD, Guang Yang, PhD

Blood (2015) 126 (23): 1563.

https://doi.org/10.1182/blood.V126.23.1563.1563

Published: 2015

NARROW

Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia

Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia

The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTK Cys481 ibrutinib resistance

Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia

Clinical and Genomic Factors Are Predictive of Response and Prognostic of Progression-Free Survival in Patients with Waldenström Macroglobulinemia Treated with Ibrutinib

CXCR4 Mutational Status Does Not Impact Outcomes in Patients with Waldenstrom Macroglobulinemia Treated with Proteasome Inhibitors

A Novel HCK and BTK Dual Inhibitor Kin-8194 Shows Superior Activity over Ibrutinib and Overcomes BTK C481S Mediated Ibrutinib Resistance in Vitro and In Vivo in MYD88 Mutated B-Cell Lymphomas

Mutated MYD88 Regulates HCK Pro-Survival Signaling through JunB in MYD88 Mutated B-Lymphoma Cells

BTK Cys481Ser drives ibrutinib resistance via ERK1/2 and protects BTK wild-type MYD88-mutated cells by a paracrine mechanism

Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia

Molecular Basis of Ibrutinib Resistance in Waldenstrom's Macroglobulinemia

Acquisition of BTK C481S Produces Resistance to Ibrutinib in MYD88 Mutated WM and ABC DLBCL Cells That Is Accompanied By ERK1/2 Hyperactivation, and Is Targeted By the Addition of the ERK1/2 Inhibitor Ulixertinib

HCK Transcription Is Regulated By AP1, NF-Kb and STAT3 Transcription Factors in MYD88 Mutated WM and ABC-DLBCL Cells

Mutated MYD88 Zygosity and CXCR4 Mutation Status Are Important Determinants of Ibrutinib Response and Progression Free Survival in Waldenstrom's Macroglobulinemia

Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib

HCK Is a Highly Relevant Target of Ibrutinib in MYD88 Mutated Waldenstrom's Macroglobulinemia and Diffuse Large B-Cell Lymphoma

Targeting IRAK1/IRAK4 Signaling in Waldenstrom's Macroglobulinemia

The Clonal Architecture of CXCR4mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability

Targeting Myddosome Self-Assembly in Waldenstrom's Macroglobulinemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only